Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tazarotene for Prevention of Regorafenib-Induced HFSR
NCT04071756Phase 2Terminated
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Dec 2019
- Primary completion
- Jun 2021
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Hand-foot skin reaction (HFSR) comparing Tazarotene + Urea with Placebo + Urea (2 arms). Primary endpoints: Grade 2 or Higher Hand-Foot Skin Reaction Rate at 8 weeks and All Grade Hand-Foot Skin Reaction Rate at 8 weeks. Started Dec 2019; status: terminated.
02
Drugs
tazarotene
03
Conditions
Hand-foot skin reaction (HFSR)
Beyond the preview
Go deeper on NCT04071756.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04071756.